Dexcom Inc
DXCM70.555USD
-0.824-1.16%
Horário de mercado （ET）Cotações atrasadas em 15 min
27.57BValor de mercado
47.84P/L TTM
Mais detalhes de Dexcom Inc Empresa
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Informações da empresa
Código da empresaDXCM
Nome da EmpresaDexcom Inc
Data de listagemApr 14, 2005
Fundado em1999
CEOMr. Kevin R. Sayer
Número de funcionários10300
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 14
Endereço6340 Sequence Dr
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Telefone18582000200
Sitehttps://www.dexcom.com/
Código da empresaDXCM
Data de listagemApr 14, 2005
Fundado em1999
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Eric J. Topol, M.D.
Dr. Eric J. Topol, M.D.
Independent Director
Independent Director
380.55K
+0.77%
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
276.26K
+6.52%
Mr. Kevin R. Sayer
Mr. Kevin R. Sayer
Chairperson of the Board, President, Chief Executive Officer
Chairperson of the Board, President, Chief Executive Officer
233.94K
+11.70%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Lead Independent Director
Lead Independent Director
59.37K
-4.34%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
58.63K
+5.18%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
41.94K
+7.44%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
40.15K
+34.41%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
39.70K
+8.30%
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Independent Director
Independent Director
23.00K
-1.51%
Mr. Kyle Malady
Mr. Kyle Malady
Independent Director
Independent Director
18.14K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Eric J. Topol, M.D.
Dr. Eric J. Topol, M.D.
Independent Director
Independent Director
380.55K
+0.77%
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
276.26K
+6.52%
Mr. Kevin R. Sayer
Mr. Kevin R. Sayer
Chairperson of the Board, President, Chief Executive Officer
Chairperson of the Board, President, Chief Executive Officer
233.94K
+11.70%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Lead Independent Director
Lead Independent Director
59.37K
-4.34%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
58.63K
+5.18%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
41.94K
+7.44%
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Distributor
3.43B
85.05%
Direct
602.90M
14.95%
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.89B
71.65%
Outside of United states
1.14B
28.35%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Distributor
3.43B
85.05%
Direct
602.90M
14.95%
Acionista
Tempo de atualização: sex, 21 de fev
Tempo de atualização: sex, 21 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
11.82%
BlackRock Institutional Trust Company, N.A.
6.17%
State Street Global Advisors (US)
4.26%
Baillie Gifford & Co.
3.73%
Capital Research Global Investors
3.67%
Other
70.36%
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
11.82%
BlackRock Institutional Trust Company, N.A.
6.17%
State Street Global Advisors (US)
4.26%
Baillie Gifford & Co.
3.73%
Capital Research Global Investors
3.67%
Other
70.36%
Tipo
Acionista
Proporção
Investment Advisor
44.84%
Investment Advisor/Hedge Fund
35.69%
Hedge Fund
6.59%
Research Firm
3.56%
Pension Fund
2.27%
Bank and Trust
1.61%
Sovereign Wealth Fund
1.44%
Individual Investor
0.38%
Venture Capital
0.34%
Other
3.27%
Participação acionária institucional
Tempo de atualização: dom, 19 de jan
Tempo de atualização: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
2198
383.01M
97.68%
-27.58M
2024Q4
2220
380.88M
97.47%
-26.96M
2024Q3
2145
382.31M
97.83%
-30.58M
2024Q2
2115
397.02M
99.11%
-4.31M
2024Q1
2093
389.18M
98.33%
-19.87M
2023Q4
2081
398.01M
103.26%
+83.33K
2023Q3
1994
389.89M
100.89%
-11.88M
2023Q2
1952
389.17M
100.78%
-12.73M
2023Q1
1908
390.83M
100.84%
-11.09M
2022Q4
1889
389.49M
100.81%
-14.66M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
46.36M
11.82%
-900.98K
-1.91%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
24.18M
6.17%
+3.21K
+0.01%
Dec 31, 2024
State Street Global Advisors (US)
16.69M
4.26%
+19.76K
+0.12%
Dec 31, 2024
Baillie Gifford & Co.
14.61M
3.73%
-404.87K
-2.70%
Dec 31, 2024
Capital Research Global Investors
14.37M
3.67%
-3.58M
-19.93%
Dec 31, 2024
Sands Capital Management, LLC
11.11M
2.83%
+790.30K
+7.66%
Dec 31, 2024
Geode Capital Management, L.L.C.
9.99M
2.55%
+56.09K
+0.56%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
8.08M
2.06%
+108.41K
+1.36%
Feb 28, 2025
Nuveen LLC
7.82M
2%
+61.83K
+0.80%
Dec 31, 2024
Jennison Associates LLC
7.64M
1.95%
+710.86K
+10.25%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
First Trust Nasdaq Lux Digi Health Solutions ETF
9.74%
Simplify Market Neutral Equity Long/Short ETF
9%
Langar Global HealthTech ETF
6.72%
Global X Internet of Things ETF
4.93%
Touchstone Sands Capital US Select Growth ETF
4.63%
Harbor Health Care ETF
4.29%
Motley Fool Mid-Cap Growth ETF
3.88%
Fidelity Digital Health ETF
3.8%
Motley Fool Global Opportunities ETF
3.63%
Global X Telemedicine & Digital Health ETF
3.55%
Ver Mais
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção9.74%
Simplify Market Neutral Equity Long/Short ETF
Proporção9%
Langar Global HealthTech ETF
Proporção6.72%
Global X Internet of Things ETF
Proporção4.93%
Touchstone Sands Capital US Select Growth ETF
Proporção4.63%
Harbor Health Care ETF
Proporção4.29%
Motley Fool Mid-Cap Growth ETF
Proporção3.88%
Fidelity Digital Health ETF
Proporção3.8%
Motley Fool Global Opportunities ETF
Proporção3.63%
Global X Telemedicine & Digital Health ETF
Proporção3.55%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 28, 2022
Split
1>4
Data
Tipo
Proporção
Mar 28, 2022
Split
1>4